U.S. Physical Therapy, Inc.

U.S. Physical Therapy, Inc. (USPH) Market Cap

U.S. Physical Therapy, Inc. has a market capitalization of $1.20B.

Price: $79.06

-1.07 (-1.34%)

Market Cap: 1.20B

NYSE · time unavailable

CEO: Christopher J. Reading

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1992-05-29

Website: https://www.usph.com

U.S. Physical Therapy, Inc. (USPH) - Company Information

Market Cap: 1.20B|Sector: Healthcare

Company Profile

U.S. Physical Therapy, Inc., through its various subsidiaries, manages a network of outpatient physical therapy facilities. These clinics deliver a range of services, including rehabilitation before and after surgery, treatment for musculoskeletal conditions, recovery from sports-related trauma, proactive health measures, assistance for workers recovering from injuries, and care for neurological conditions. The company's business is divided into two primary divisions: Physical Therapy Operations and Industrial Injury Prevention Services. Within its industrial segment, it provides specialized services like on-site injury avoidance and recovery programs, strategies for enhancing physical performance, pre-employment screening tests, assessments of an individual's work capacity, and workplace ergonomic reviews. These offerings are delivered by licensed physical therapists and expert certified athletic trainers to a diverse clientele, including Fortune 500 corporations, insurance providers, and their associated contractors. By the end of 2021, specifically December 31st, the company had established 591 operational clinics across 39 states, in addition to overseeing 35 other physical therapy sites. Established in 1990, the company maintains its headquarters in Houston, Texas.

Analyst Sentiment

88%
Strong Buy

From 7 Active Polls

1Y Forecast: $96.00

▲ +21.4% Potential Upside

Consensus Target Metrics

Low Bound

$90

Median

$96

High Bound

$102

Average

$96

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$96.00
▲ +21.43% Upside
Low Target
$90.00
14% Risk
Median Target
$96.00
21% Mid
High Target
$102.00
29% Max
Consensus
Buy
10 / 13 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,2031,1371,1851,2921,1881,0951,3361,2761,376
Enterprise Value ($M)1,5381,4711,5751,5691,4601,3631,5901,4131,522
Price to Earnings Ratio (P/E)158.12-156.17-44.3744.2433.7122.6142.6554.2548.57
Price/Earnings-to-Growth Ratio (PEG)-1.884.425.77107.596.57
Price to Sales Ratio (P/S)1.655.735.857.877.247.187.417.598.23
Price to Book Ratio (P/B)2.562.422.492.562.372.202.732.642.84
Price to Free Cash Flow Ratio (P/FCF)17.99-829.8756.4182.6637.60-150.9478.9865.1151.31
Enterprise Value to Sales (EV/Sales)7.427.779.568.898.948.818.419.11
Enterprise Value to EBITDA (EV/EBITDA)14.8576.0271.7950.4246.8953.5161.0375.4271.51
Debt to Equity Ratio3.230.770.890.610.610.620.600.530.53

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 US PHYSICAL THERAPY INC (USPH) — Investment Overview

🧩 Business Model Overview

US Physical Therapy operates outpatient physical therapy clinics and generates revenue by delivering physician-prescribed therapy services to patients across common orthopedic and musculoskeletal use cases. The operating model is clinic-based: a network of physical therapists and support staff deliver treatment plans, document outcomes, and coordinate care pathways that feed referral relationships. Demand is driven by physician referrals (orthopedics, primary care, sports medicine), payer coverage rules, and patient access within defined geographic markets. Over time, clinic-level operational execution—therapist scheduling, throughput, documentation quality, and payer contracting—supports patient volume stability and cost discipline.

💰 Revenue Streams & Monetisation Model

Revenue is primarily transactional in nature, tied to patient visits and therapy services billed under Medicare and commercial payer contracts. While therapy episodes can be time-bound, practical monetisation tends to exhibit some persistence through (i) repeat care within a clinical pathway and (ii) ongoing referral inflows from provider partners for recurring musculoskeletal demand. Margin drivers largely stem from labor productivity (therapist hours, utilization, documentation efficiency), clinic-level rent and occupancy leverage, and payer reimbursement mix (rates under Medicare versus commercial contracts). Because reimbursement is largely functionally “per service,” cost control and staffing efficiency are central to operating leverage.

🧠 Competitive Advantages & Market Positioning

USPH’s competitive positioning is best understood through healthcare-specific “operating ecosystem” moats rather than a patented product. The most durable advantages are:

  • High Barriers to Entry (Clinical operations + compliance): Building compliant, high-throughput outpatient therapy operations requires recruiting and retaining licensed therapists, mastering documentation standards, and sustaining billing accuracy across payer rules. Competitors can open clinics, but replicating consistent documentation, scheduling efficiency, and payer performance takes time.
  • Integrated Ecosystem (Referral relationships and care continuity): Clinic networks can develop durable relationships with physicians and provider groups, supporting referral stability. This ecosystem effect is reinforced when outcomes, responsiveness, and communication standards are consistently delivered.
  • Cost/Execution Advantage (Density and throughput): Regional density can improve management focus, staffing flexibility, and marketing efficiency per patient. Higher clinic productivity and better payer contracting execution can protect margins in a reimbursement-constrained environment.

Competitive benchmarking:

  • Select Medical (SEM): A scaled operator with broader rehabilitation offerings and a wider geographic footprint. USPH focuses more narrowly on outpatient physical therapy, which can concentrate operational learning and clinic-level execution in its core segment.
  • Encompass Health (EHC): Primarily a provider of inpatient rehabilitation services, with less direct parity to outpatient-only physical therapy economics. USPH competes for musculoskeletal rehabilitation demand through outpatient access and physician referral pathways.
  • ATI Physical Therapy: A major outpatient physical therapy brand. While competition can intensify in overlapping markets, USPH’s differentiation typically rests on clinic-level operating discipline and localized referral relationships rather than broad service branding alone.

Overall, the “moat” is less about switching costs for patients and more about sustained ability to attract referrals, deliver compliant high-quality therapy, and run clinics efficiently within payer constraints.

🚀 Multi-Year Growth Drivers

  • Secular increase in musculoskeletal demand: Aging demographics and the prevalence of chronic pain and degenerative conditions expand the addressable need for physical therapy services.
  • Shift from higher-acuity sites to outpatient care: Delivery models that emphasize outpatient rehab access support volume expansion as payers and providers manage post-acute cost and capacity.
  • Under-penetration of outpatient PT: In many markets, patient access and referral practices drive utilization gaps; effective operators can capture demand by improving referral workflows and patient throughput.
  • Geographic and clinic expansion: New clinic openings and strategic acquisitions can extend the network into markets with sufficient physician density and payer coverage.
  • Value-based care alignment: Clinics that demonstrate consistent documentation and care pathways can better navigate payer scrutiny and utilization management over time.

⚠ Risk Factors to Monitor

  • Reimbursement and policy pressure: Changes to Medicare payment rates, therapy caps/thresholds history, and evolving coverage rules (including documentation and medical necessity standards) can pressure net revenue per visit.
  • Labor market constraints: Physical therapist labor availability and wage inflation directly affect clinic economics, especially in markets where competition for clinicians is high.
  • Utilization management and prior authorization: Payer and employer strategies that tighten utilization can reduce visit volume or alter treatment plan patterns.
  • Operating leverage risk: Clinic ramp-up costs, staffing misalignment, and occupancy leverage can dilute returns if new locations underperform.
  • Competitive intensity: Scaled rivals can respond with aggressive clinic placement, payer contracting, or referral outreach, leading to margin compression in overlapping geographies.
  • Regulatory and billing compliance: Therapy billing depends on rigorous documentation and medical necessity. Compliance failures can create financial and reputational exposure.

📊 Valuation & Market View

Equity valuation for outpatient healthcare providers typically reflects operating performance and durability of margins rather than technology-style growth assumptions. Investors often focus on EV/EBITDA and P/S as high-level frameworks, with the key value drivers being (i) same-clinic revenue stability, (ii) operating margin sustainability, (iii) labor cost control and productivity, (iv) payer mix quality, and (v) capital efficiency of clinic expansion. Over time, valuation tends to respond to confidence in incremental clinic returns, the stability of reimbursement economics, and the ability to manage clinician turnover and scheduling productivity.

🔍 Investment Takeaway

US Physical Therapy offers an outpatient physical therapy growth platform where the primary investment case rests on operational barriers to entry, referral-driven clinic ecosystems, and execution-driven margin resilience. The long-term opportunity is supported by structural demand for musculoskeletal rehabilitation and continued outpatient shift, while risks center on reimbursement policy, labor economics, and compliance discipline. A credible investment outlook depends on sustaining clinic productivity and payer contracting outcomes while expanding within markets that support durable referral density.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for USPH.

businesswire.com2026-07-22

U.S. Physical Therapy, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call Dates

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three and six months ended June 30, 2026, on Wednesday, August 5, 2026, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 6, 2026. Conference Call    Date:    Thursd.

businesswire.com2026-07-02

U.S. Physical Therapy Announces the Acquisition of a Twelve-Clinic Physical Therapy Practice

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced the acquisition of a twelve-clinic physical therapy practice, effective July 1, 2026. USPH acquired a 67% equity interest, with 33% retained by the current owners. The practice currently generates approximately 112,000 annual visits and $12 million in annual reve.

seekingalpha.com2026-05-22

U.S. Physical Therapy: The Valuation Reset Changes The Story (Rating Upgrade)

U.S. Physical Therapy, Inc. has seen valuation multiples compress significantly despite continued revenue growth and new strategic initiatives. U.S. Physical Therapy reported Q1 2026 revenue of $198.3M (+7.9% YoY) but missed EPS expectations due to higher costs from acquisitions and clinic startups. Management is pursuing hospital partnerships and shifting toward private insurance, aiming to boost clinic utilization and reduce reliance on Medicare/Medicaid.

businesswire.com2026-05-14

U.S. Physical Therapy Presented at the BofA Securities 2026 Healthcare Conference

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that Chris Reading, Chairman and Chief Executive Officer, presented at the BofA Securities 2026 Healthcare Conference held on May 13, 2026. The presentation included a discussion of the overall operating environment in healthcare, the Company's key initiatives and a broad.

seekingalpha.com2026-05-08

U.S. Physical Therapy, Inc. (USPH) Q1 2026 Earnings Call Transcript

U.S. Physical Therapy, Inc. (USPH) Q1 2026 Earnings Call Transcript

zacks.com2026-05-06

U.S. Physical Therapy (USPH) Q1 Earnings and Revenues Lag Estimates

U.S. Physical Therapy (USPH) came out with quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.48 per share a year ago.

zacks.com2026-05-06

Here's What Key Metrics Tell Us About U.S. Physical Therapy (USPH) Q1 Earnings

While the top- and bottom-line numbers for U.S. Physical Therapy (USPH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

businesswire.com2026-05-06

U.S. Physical Therapy Reports Record First Quarter Revenue, Reaffirms Full Year Guidance

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (“IIP”), today reported results for the first quarter ended March 31, 2026 (“Q1 2026”). Total net revenue of $198.3 million for Q1 2026, a 7.9% increase over the first quarter ended March 31, 2025 (“Q1 2025”). Net income attributable to USPH shareholders of $5.0 million for Q1 20.

businesswire.com2026-04-22

U.S. Physical Therapy, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call Dates

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, after the stock market closes, with the conference call to follow the next morning, on Thursday, May 7, 2026. Conference Call Date: Thursday, May 7, 2026  .

businesswire.com2026-04-15

U.S. Physical Therapy Announces $450 Million Credit Facility

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced the closing of a $450 million, five-year credit facility that includes a $175 million term loan and a $275 million revolver with a maturity date of April 14, 2031. Based on strong lender support, the credit facility was upsized from its initial $400 million launc.

defenseworld.net2026-03-30

JPMorgan Chase & Co. Purchases 56,752 Shares of U.S. Physical Therapy, Inc. $USPH

JPMorgan Chase and Co. lifted its position in U.S. Physical Therapy, Inc. (NYSE: USPH) by 106.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,837 shares of the company's stock after buying an additional 56,752 shares during the quarter. JPMorgan

defenseworld.net2026-03-16

Analysts Set U.S. Physical Therapy, Inc. (NYSE:USPH) Target Price at $104.50

U.S. Physical Therapy, Inc. (NYSE: USPH - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy

businesswire.com2026-03-12

U.S. Physical Therapy Presented at the Barclays 28th Annual Global Healthcare Conference

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that Chris Reading, Chairman and Chief Executive Officer, presented at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 783 outpatient physi.

fool.com2026-03-04

$9 Million Exit: Investor Dumps 110,000 Shares of U.S. Physical Therapy as Stock Lags Broader Market

4D Advisors exited 110,000 shares in U.S. Physical Therapy during the fourth quarter. The quarter-end position value decreased by $9.34 million as a result.

zacks.com2026-03-04

Wall Street Analysts Believe U.S. Physical Therapy (USPH) Could Rally 26.52%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in U.S. Physical Therapy (USPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"US Pharmacy (USPH) reported Q1 2026 revenue of $164.3M and net income of $5.0M (EPS reported as -$0.12). On a year-over-year basis, revenue rose to $164.3M vs $152.5M in Q1 2025 (+7.7% YoY), while net income declined from $9.9M to $5.0M (-49.1% YoY). Sequentially, revenue fell from $202.7M in Q4 2025 (-19.0% QoQ), and net income swung from a loss of -$10.5M in Q4 to +$5.0M in Q1 (+$15.5M QoQ). Profitability softened: gross margin slipped to 19.9% from 20.7% in Q4 2025 and 20.4% in Q1 2025, and net margin contracted to 3.1% from -5.2% (Q4) but below the 6.5% seen in Q1 2025. Operating income improved QoQ (from -$22.0M in Q4 to +$12.5M in Q1) but remained down YoY (operating income $22.0M in Q1 2025 vs $12.5M in Q1 2026). Cash flow quality was mixed: operating cash flow was $3.8M and free cash flow was -$1.6M in Q1 2026, versus strong Q4 2025 free cash flow of $21.0M (and -$7.3M in Q1 2025). Dividends were paid ($7.0M) while share repurchases were none in the quarter. Balance sheet leverage deteriorated with higher net debt to $140.9M (vs $390.2M net debt in Q4 2025), while equity increased modestly to $783M from $770M. Shareholder returns: price is up +11.9% over 1Y (no >20% momentum boost). Dividend yield is ~0.6%, so total shareholder return is likely modest."

Revenue Growth

Positive

Revenue up +7.7% YoY ($164.3M vs $152.5M in Q1’25) but down -19.0% QoQ ($164.3M vs $202.7M in Q4’25), indicating volatility.

Profitability

Caution

Net margin declined to 3.1% from 6.5% YoY and gross margin softened (19.9% vs 20.4% YoY). QoQ improved from a net loss to profit, but the trend over the year is weaker.

Cash Flow Quality

Caution

Q1’26 operating cash flow was $3.8M with free cash flow of -$1.6M (vs +$21.0M FCF in Q4’25). Dividends ($7.0M) were paid, but cash generation in the quarter was limited.

Leverage & Balance Sheet

Neutral

Total assets rose to $1.24B and equity increased to $782M. Net debt improved sequentially (from $390M to $141M), suggesting some de-leveraging versus Q4, but balance sheet still carries meaningful debt.

Shareholder Returns

Fair

1Y price change is +11.9% (no strong momentum >20%). Dividend yield is ~0.6%; buybacks were 0 in Q1’26, so total returns look modest.

Analyst Sentiment & Valuation

Caution

Price targets show a consensus of $102 vs the current price of $76.57, implying upside on paper; however, valuation support is tempered by recent EPS/reporting inconsistencies and negative/volatile cash flow.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

USPH delivered Q1 2026 results largely “on budget,” with revenue up 7.9% to $198M, visits up 6.9%, and net revenue per visit rising to $106.49 (+~$0.83). The quarter’s major operational detractor was weather that removed ~31,000 visits, implying ~$3.3M revenue headwind and margin drag because staffing costs largely remain fixed. Despite that, adjusted EBITDA grew to $20.2M (+$0.7M). Physical therapy margins declined (16.1% vs 16.8%), while IIP strength was notable: revenue +11.8% and IIP margin up 180 bps to 20.4%. Management reaffirmed full-year 2026 adjusted EBITDA of $102M–$106M and emphasized initiatives (front-desk semi-virtualization, AI documentation, remote monitoring, and cash-based programs) as benefits that will ramp later in the year. Hospital affiliations (NYU and Gulf Coast) are progressing; first Metro phasing started this week, with the $7M annualized impact expected to flow more meaningfully into Q4 after conversions complete by end of Q3.

AI IconGrowth Catalysts

  • Physical therapy: revenue +7.2% YoY with same-store revenue +8.2% driven by patient volume +6.9% and visits/clinic/day rising to 31.8
  • Injury prevention (IIP): revenue +11.8% YoY; same-store IIP +8.2% excluding the Q1 2026 acquisition; IIP margin +180 bps to 20.4%
  • Cash-based program expansion across top partnerships (laser/shockwave/dry needling) producing hundreds of thousands of dollars annually at partners starting from zero
  • Hospital alliances ramp: started phasing in first Metro facilities into NYU conversion process in Q1/Q2 timeframe; additional facilities expected over next few months

Business Development

  • Hospital affiliation: NYU transition process began; initial set of clinics converting with phase-in starting 'this week'
  • Hospital affiliation: Gulf Coast region opportunity; potential start 'in June or July' depending on near-term progress
  • Partnership expansion: cash-based program rollout with 30 of top 40 partnerships in Houston (welcome wear, AI documentation, laser/shockwave focus)
  • Acquisitions: January acquired 50% interest in an eight-clinic PT practice (about $8M revenue, ~60,000 visits)
  • Acquisitions: January acquired 70% interest in an industrial injury prevention business (about $7M revenue)
  • IIP acquisition: 'latest IIP New York-based acquisition' provided partial-quarter contribution in Q1

AI IconFinancial Highlights

  • Total revenue $198M, +7.9% YoY
  • Physical therapy revenue $168M, +7.2% YoY; mature clinic revenue +2.5%
  • Visits: 1.543M total visits, +6.9% YoY; visits/clinic/day 31.8 vs 31.2
  • Net revenue per visit $106.49, up from $105.66; commercial revenue per visit +3.4%; commercial is ~50% of payer mix
  • Medicare rate: early impact of expected +1.75% Medicare rate increase; full benefit expected to build as year progresses (payment lag)
  • Medicaid rate: blended rate drag—Medicaid down; management to monitor 'as the year progresses' (single-digit change, not large portion)
  • IIP margin +180 bps to 20.4% (vs 18.6% prior year); PT margin decreased to 16.1% (from 16.8%), implying headwind in Q1 from weather and cost timing
  • Weather impact: lost ~31,000 visits; blended average rate 'somewhat north of $3M' (~$3.3M) revenue headwind; management noted margin drag due to paying salaried staff regardless
  • Adj. EBITDA guidance reaffirmed: $102M to $106M for full-year 2026
  • Adj. EBITDA Q1: $20.2M, +$0.7M vs Q1 2025; operating results per share $0.46 vs $0.48 prior year; GAAP EPS $-0.12 vs $0.80 prior year
  • Tax: income tax rate 32.3% vs 28.1%; elevated due to negative discrete tax items on lower pretax income

AI IconCapital Funding

  • Equity repurchases/purchases of noncontrolling interest: ~$14M spend to purchase noncontrolling interests in two partnerships
  • Credit facility refinancing: completed renegotiation; announced 04/15/2026 five-year $450M credit facility, maturity 04/14/2031 (upsized from initial $400M launch; improved pricing vs prior facility)
  • Borrowings: $204M on credit facility at Q1 end vs $162M at year-end 2025
  • Cash: $28M at end of Q1 2026 vs $36M at year-end 2025

AI IconStrategy & Ops

  • Semi-virtualization of front desk to reduce labor and improve authorization consistency (rate impact via authorization consistency)
  • AI-assisted ambient listening documentation to reduce clinician head-down time and improve patient interfacing/productivity
  • Reengagement of remote therapeutic monitoring for traditional Medicare population after CMS rule revision (beginning Jan 2026)
  • Workday ERP implementation progress; expected go-live end of 2027 (HR and finance) to modernize systems and improve efficiency
  • Recruitment/retention: turnover sub-18% in Q1 (lowest measured since measuring); expected to help busiest months
  • Technology and people investments front-loaded in Q1 to drive benefits later in 2026

AI IconMarket Outlook

  • Full-year 2026 adjusted EBITDA reaffirmed at $102M to $106M
  • Hospital alliances: initial Metro facilities conversion into NYU phase-in began 'literally this week'; Gulf Coast deal could begin 'June or July'; full quarterly run-rate of $7M hospital impact expected to start in Q4 after conversion materially complete by end of Q3
  • Medicare rate impact: expect full +1.75% Medicare rate build 'as the year progresses' due to deductible/payment lag

AI IconRisks & Headwinds

  • Weather: Q1 experienced weather-related lost visits (~31,000) causing revenue loss (~$3.3M blended-rate basis) and margin drag from continued pay for salaried staff; no similar weather expected in Q2 per management
  • PT operating margin pressure: PT margin decreased 180 bps to 16.1% (from 16.8%); management cited expense carry and upfront investments/technology initiative costs
  • Medicaid rate weakness: blended rate drag due to Medicaid rate down 'a few percent' (single-digit); management will monitor regional mix/pricing changes in Q2
  • Hospital alliance timing variability: management stated cadence not predictable; transactions require long enterprise processes with large legal/constituent involvement
  • GAAP EPS distortion from accounting: redeemable noncontrolling interest revaluation and contingent earnout fair value swings (loss on change in fair value $2.0M vs gain $4.8M in prior year; GAAP EPS negative -0.12)

Q&A: Analyst Interest

  • Weather-to-EBITDA bridge: Management said Q1 came nearly exactly as budgeted, with ~31,000 lost visits creating revenue drag of ~$3.3M; margin pressure occurred because salaried staffing continues. Acquisitions and hospital phasing were already baked into full-year guidance; no extra Q1 inclusion assumptions.
  • Hospital ramp mechanics and annualization: Analysts probed how $7M annualized hospital impact flows through 2026. Management explained conversions started in Q2, expected materially complete by end of Q3, and thus run-rate benefit appears in Q4, ramping sequentially quarter-over-quarter rather than by quarter guidance.
  • Expense drivers and run-rate normalization: Asked why rent/supplies/other and corporate expenses ran hot YoY. Management attributed partial weather-related revenue shortfall causing deleveraging on fixed costs, plus upfront investments in 2026 initiatives. Additional contract labor appeared needed in certain partnerships due to volume execution and utilization.

Sentiment: MIXED

Note: This summary was synthesized by AI from the USPH Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for USPH.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (USPH)

© 2026 Stock Market Info — U.S. Physical Therapy, Inc. (USPH) Financial Profile